A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment

The CXC chemokine receptor type 4 (CXCR4) receptor and its ligand, CXCL12, are overexpressed in various cancers and mediate tumor progression and hypoxia-mediated resistance to cancer therapy. While CXCR4 antagonists have potential anticancer effects when combined with conventional anticancer drugs,...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jen-Shin, Chang, Chih-Chun, Wu, Chien-Huang, Dinh, Trinh Kieu, Jan, Jiing-Jyh, Huang, Kuan-Wei, Chou, Ming-Chen, Shiue, Ting-Yun, Yeh, Kai-Chia, Ke, Yi-Yu, Yeh, Teng-Kuang, Ta, Yen-Nhi Ngoc, Lee, Chia-Jui, Huang, Jing-Kai, Sung, Yun-Chieh, Shia, Kak-Shan, Chen, Yunching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020795/
https://www.ncbi.nlm.nih.gov/pubmed/33753481
http://dx.doi.org/10.1073/pnas.2015433118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020795/
https://www.ncbi.nlm.nih.gov/pubmed/33753481
http://dx.doi.org/10.1073/pnas.2015433118

Ejemplares similares